Literature DB >> 19999682

Premature discharge from methadone treatment: patient perspectives.

Heather Schacht Reisinger1, Robert P Schwartz, Shannon Gwin Mitchell, James A Peterson, Sharon M Kelly, Kevin E O'Grady, Erica A Marrari, Barry S Brown, Michael H Agar.   

Abstract

Longer retention in drug abuse treatment is associated with better patient outcomes, and research indicates the first 12 months of methadone treatment are critical to patient success. Nevertheless, large-scale multisite longitudinal studies over the past three decades indicate that the majority of patients drop out during the first year of methadone treatment. Through an examination of 42 qualitative interviews with patients prematurely discharged from six methadone treatment programs in Baltimore, this study highlights factors patients describe as contributing to their reasons for being discharged within the first 12 months of the treatment. The two most consistent themes are program-related factors and incarceration. The former factors are richly described through patients' words and underscore the ways in which patients' perceptions of control exerted by the program and by the medication and misunderstandings of program structure can lead to premature discharge. Patients' reasons for discharge were compared to counselors' reasons as indicated in discharge summary forms. An analysis of the patterns of agreement and disagreement are presented. Patient-centered program and policy implications are discussed.

Entities:  

Keywords:  Discharge; Ethnography; Methadone treatment

Mesh:

Substances:

Year:  2009        PMID: 19999682      PMCID: PMC2796585          DOI: 10.1080/02791072.2009.10400539

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  30 in total

1.  Active heroin injectors' perceptions and use of methadone maintenance treatment: cynical performance or self-prescribed risk reduction?

Authors:  S Koester; K Anderson; L Hoffer
Journal:  Subst Use Misuse       Date:  1999-12       Impact factor: 2.164

2.  The Key Extended Entry Program (KEEP): from the community side of the bridge.

Authors:  B M Fallon
Journal:  Mt Sinai J Med       Date:  2001-01

3.  Factors associated with methadone maintenance treatment retention among street-recruited injection drug users.

Authors:  Robert E Booth; Karen F Corsi; Susan K Mikulich-Gilbertson
Journal:  Drug Alcohol Depend       Date:  2004-05-10       Impact factor: 4.492

4.  Drug abuse treatment in the context of correctional surveillance.

Authors:  D N Nurco; T E Hanlon; R W Bateman; T W Kinlock
Journal:  J Subst Abuse Treat       Date:  1995 Jan-Feb

5.  Treatment services in two national studies of community-based drug abuse treatment programs.

Authors:  R M Etheridge; S G Craddock; G H Dunteman; R L Hubbard
Journal:  J Subst Abuse       Date:  1995

6.  Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Robert P Schwartz
Journal:  J Psychoactive Drugs       Date:  2009-06

7.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.

Authors:  D S Metzger; G E Woody; A T McLellan; C P O'Brien; P Druley; H Navaline; D DePhilippis; P Stolley; E Abrutyn
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-09

8.  Jail management of arrestees/inmates enrolled in community methadone maintenance programs.

Authors:  Kevin Fiscella; Andrew Moore; Judith Engerman; Sean Meldrum
Journal:  J Urban Health       Date:  2004-12       Impact factor: 3.671

9.  Methadone dosage and retention of patients in maintenance treatment.

Authors:  J R Caplehorn; J Bell
Journal:  Med J Aust       Date:  1991-02-04       Impact factor: 7.738

Review 10.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  R P Mattick; C Breen; J Kimber; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  37 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study.

Authors:  Ryan McNeil; Thomas Kerr; Solanna Anderson; Lisa Maher; Chereece Keewatin; M J Milloy; Evan Wood; Will Small
Journal:  Soc Sci Med       Date:  2015-04-07       Impact factor: 4.634

3.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

4.  Preliminary findings on the association between clients' perceived helpfulness of substance abuse treatment and outcomes: does race matter?

Authors:  LaTrice Montgomery; Blair Sanning; Nicole Litvak; Erica N Peters
Journal:  Drug Alcohol Depend       Date:  2014-04-05       Impact factor: 4.492

5.  Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States.

Authors:  Jeannia J Fu; Nickolas D Zaller; Michael A Yokell; Alexander R Bazazi; Josiah D Rich
Journal:  J Subst Abuse Treat       Date:  2013-02-22

6.  Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.

Authors:  Sarah A Weicker; Kanna Hayashi; Cameron Grant; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2019-10-25       Impact factor: 4.492

7.  Patient-centered methadone treatment: a randomized clinical trial.

Authors:  Robert P Schwartz; Sharon M Kelly; Shannon G Mitchell; Jan Gryczynski; Kevin E O'Grady; Devang Gandhi; Yngvild Olsen; Jerome H Jaffe
Journal:  Addiction       Date:  2016-11-10       Impact factor: 6.526

8.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Authors:  Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner
Journal:  Addiction       Date:  2020-02-24       Impact factor: 6.526

9.  Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.

Authors:  Eve Wittenberg; Jeremy W Bray; Brandon Aden; Achamyeleh Gebremariam; Bohdan Nosyk; Bruce R Schackman
Journal:  Addiction       Date:  2015-12-17       Impact factor: 6.526

10.  Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.

Authors:  Jan Gryczynski; Jerome H Jaffe; Robert P Schwartz; Kristi A Dušek; Nishan Gugsa; Cristin L Monroe; Kevin E O'Grady; Yngvild K Olsen; Shannon Gwin Mitchell
Journal:  Am J Addict       Date:  2013 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.